Notes in Bladder cancer

To Subscribe, use this Key

Status	Last Update	Fields
Published	02/18/2024	GU \| Bladder \| Muscle invasive bladder cancer \| James trial \| NEJM 2012
Published	02/18/2024	GU \| Bladder \| 1.2 \| Epidemiology
Published	02/18/2024	GU \| Bladder \| 1.3 \| Risk factors
Published	02/18/2024	GU \| Bladder \| 1.4.1 \| Pathologic classification
Published	02/18/2024	GU \| Bladder \| 1.1 \| Anatomy
Published	02/18/2024	GU \| Bladder \| 1.5.2 \| Urothelial tumours overview
Published	02/18/2024	GU \| Bladder \| 1.5.3.1 \| Urothelial tumours \| Noninvasive \| Papillary \| Overview
Published	02/18/2024	GU \| Bladder \| 1.5.4 \| Urothelial tumours \| Noninvasive \| Flat (CIS)
Published	02/18/2024	GU \| Bladder \| 1.5.5 \| Urothelial tumours \| Invasive
Published	02/18/2024	GU \| Bladder \| 1.5.3.2 \| Urothelial tumours \| Noninvasive \| Papillary \| Benign (papilloma or inverted papilloma)
Published	02/18/2024	GU \| Bladder \| 1.5.3.3 \| Urothelial tumours \| Noninvasive \| Papillary \| Papillary urothelial neoplasm of low malignant potential
Published	02/18/2024	GU \| Bladder \| 1.5.3.4 \| Urothelial tumours \| Noninvasive \| Papillary \| Low grade papillary urothelial carcinoma
Published	02/18/2024	GU \| Bladder \| 1.5.3.5 \| Urothelial tumours \| Noninvasive \| Papillary \| High grade papillary urothelial carcinoma
Published	02/18/2024	GU \| Bladder \| 1.6 \| Non-urothelial neoplasms of the bladder (SCC and Adenocarcinoma)
Published	02/18/2024	GU \| Bladder \| 1.7 \| Staging (AJCC 8th edition 2017)
Published	02/18/2024	GU \| Bladder \| 1.8 \| Clinical presentation
Published	02/18/2024	GU \| Bladder \| 2.1 \| Workup
Published	02/18/2024	GU \| Bladder \| 2.3 \| Prognostic factors
Published	02/18/2024	GU \| Bladder \| 1.9 \| Biologic behaviour
Published	02/18/2024	GU \| Bladder \| 2.4 \| Prognosis
Published	02/18/2024	GU \| Bladder \| 3.1 \| Management \| Overview
Published	02/18/2024	GU \| Bladder \| 3.2.1 \| NMIBC \| Incidence, classification and general management
Published	02/18/2024	GU \| Bladder \| 3.2.2 \| NMIBC \| TURBT
Published	02/18/2024	GU \| Bladder \| 3.2.3 \| NMIBC \| Adjuvant therapy post TURBT - indications
Published	02/18/2024	GU \| Bladder \| 3.2.4 \| NMIBC \| Intravesical  therapy
Published	02/18/2024	GU \| Bladder \| 3.2.5 \| NMIBC \| Adjuvant RT or chemoRT for high risk T1
Published	02/18/2024	GU \| Bladder \| 3.2.5 \| NMIBC \| Surveillance
Published	02/18/2024	GU \| Bladder \| 3.2.6 \| NMIBC \| Persistence / recurrence
Published	02/18/2024	GU \| Bladder \| 3.3.1 \| MIBC \| Cystectomy \| Surgical principles
Published	02/18/2024	GU \| Bladder \| 3.3.2 \| MIBC \| Cystectomy \| Neoadjuvant and adjuvant chemotherapy
Published	02/18/2024	GU \| Bladder \| 3.3.3 \| MIBC \| Cystectomy \| Adjuvant RT
Published	02/18/2024	GU \| Bladder \| 3.3.4 \| MIBC \| Cystectomy \| Local recurrence following cystectomy
Published	02/18/2024	GU \| Bladder \| 3.4.1 \| MIBC \| Bladder sparing \| Cystectomy vs. bladder preservation
Published	02/18/2024	GU \| Bladder \| 3.4.2 \| MIBC \| Bladder preservation \| Patient selection
Published	02/18/2024	GU \| Bladder \| 3.4.3 \| MIBC \| Bladder preservation \| Rationale and evidence
Published	02/18/2024	GU \| Bladder \| 3.4.4 \| MIBC \| Bladder preservation \| RT alone
Published	02/18/2024	GU \| Bladder \| 3.4.5 \| MIBC \| Bladder preservation \| Selective bladder sparing (UK approach)
Published	02/18/2024	GU \| Bladder \| 3.4.6 \| MIBC \| Bladder preservation \| Controversies in RT
Published	02/18/2024	GU \| Bladder \| 3.4.7 \| MIBC \| Bladder preservation \| Follow up
Published	02/18/2024	GU \| Bladder \| 3.4.8 \| MIBC \| Bladder preservation \| Management of relapse
Published	02/18/2024	GU \| Bladder \| 3.5.1 \| MIBC \| Palliative treatment
Published	02/18/2024	GU \| Bladder \| 3.6 \| MIBC \| Management of other sites and histologies
Published	02/18/2024	GU \| Bladder \| 2.2 \| Pre-treatment bladder assessment
Published	02/18/2024	GU \| Bladder \| 1.5.1 \| Urothelial tumours \| Pathogenesis
Published	02/18/2024	GU \| Bladder \| 3.2.7 \| NMIBC - role of radiothearpy (none)
Published	02/18/2024	GU \| Bladder \| 4.1 \| RT technique \| Dose and fractionation
Published	02/18/2024	GU \| Bladder \| 4.2 \| RT technique \| IMRT/VMAT vs. 3DCRT
Published	02/18/2024	GU \| Bladder \| 4.3 \| RT technique \| Bladder filling
Published	02/18/2024	GU \| Bladder \| 5 \| Outcomes
Published	02/18/2024	GU \| Bladder \| 4.4 \| RT technique \| GTV delineation and boost
Published	02/18/2024	GU \| Bladder \| 4.5 \| RT technique \| Volumes
Published	02/18/2024	GU \| Bladder \| 4.6 \| RT technique \| Target verification
Published	02/18/2024	GU \| Bladder \| 4.7 \| RT technique \| Toxicity
Published	02/18/2024	GU \| Bladder \| 4.8 \| RT technique \| Choice of concurrent chemotherapy
Published	02/18/2024	GU \| Bladder \| 6 \| Ongoing trials in Australia
Published	02/18/2024	GU \| Bladder \| 4.0 \| RT technique \| Definitive (chemo)radiotherapy
Published	02/18/2024	Urinary \| Bladder \| 1.5.6 \| Distinguishing high grade prostate from urothelial carcinoma
Published	02/18/2024	GU \| Bladder \| 1.4.2 \| Benign lesions
Published	02/18/2024	GU \| Bladder \| 3.3.2.1 \| MIBC \| Cystectomy \| Adjuvant immunotherapy
Status	Last Update	Fields